Literature DB >> 18537573

Molecular characterization of CYP2B6 substrates.

Sean Ekins1, Manisha Iyer, Matthew D Krasowski, Evan D Kharasch.   

Abstract

CYP2B6 has not been as fully characterized at the molecular level as other members of the human cytochrome P450 family. As more widely used in vitro probes for characterizing the involvement of this enzyme in the metabolism of xenobiotics have become available, the number of molecules identified as CYP2B6 substrates has increased. In this study we have analyzed the available kinetic data generated by multiple laboratories with human recombinant expressed CYP2B6 and along with calculated molecular properties derived from the ChemSpider database, we have determined the molecular features that appear to be important for CYP2B6 substrates. In addition we have applied 2D and 3D QSAR methods to generate predictive pharmacophore and 2D models. For 28 molecules with K(m) data, the molecular weight (mean +/- SD) is 253.78+/-74.03, ACD/logP is 2.68+/-1.51, LogD(pH 5.5) is 1.51+/-1.43, LogD(pH 7.4) is 2.02+/-1.25, hydrogen bond donor (HBD) count is 0.57 +/-0.57, hydrogen bond acceptor (HBA) count is 2.57+/-1.37, rotatable bonds is 3.50+/-2.71 and total polar surface area (TPSA) is 27.63+/-19.42. A second set of 15 molecules without K(m) data possessed similar mean molecular property values. These properties are comparable to those of a set of 21 molecules used in a previous pharmacophore modeling study (Ekins et al., J Pharmacol Exp Ther 288 (1), 21-29, 1999). Only the LogD and HBD values were statistically significantly different between these different datasets. We have shown that CYP2B6 substrates are generally small hydrophobic molecules that are frequently central nervous system active, which may be important for drug discovery research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537573      PMCID: PMC2426921          DOI: 10.2174/138920008784746346

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  77 in total

Review 1.  The role of CYP2B6 in human xenobiotic metabolism.

Authors:  S Ekins; S A Wrighton
Journal:  Drug Metab Rev       Date:  1999-08       Impact factor: 4.518

Review 2.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

3.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

4.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

Review 5.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.

Authors:  S Ekins; M J de Groot; J P Jones
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

6.  Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.

Authors:  K Kobayashi; T Ishizuka; N Shimada; Y Yoshimura; K Kamijima; K Chiba
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

7.  In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos.

Authors:  Jun Tang; Yan Cao; Randy L Rose; Ernest Hodgson
Journal:  Chem Biol Interact       Date:  2002-10-20       Impact factor: 5.192

8.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

9.  Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite.

Authors:  Yiding Hu; David Kupfer
Journal:  Drug Metab Dispos       Date:  2002-09       Impact factor: 3.922

Review 10.  Future directions for drug transporter modelling.

Authors:  S Ekins; G F Ecker; P Chiba; P W Swaan
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

View more
  13 in total

1.  Coumarin Derivatives as Substrate Probes of Mammalian Cytochromes P450 2B4 and 2B6: Assessing the Importance of 7-Alkoxy Chain Length, Halogen Substitution, and Non-Active Site Mutations.

Authors:  Jingbao Liu; Manish B Shah; Qinghai Zhang; C David Stout; James R Halpert; P Ross Wilderman
Journal:  Biochemistry       Date:  2016-03-24       Impact factor: 3.162

Review 2.  Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.

Authors:  Pan-Fen Wang; Alicia Neiner; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

3.  Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects.

Authors:  Jibran Y Khokhar; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2010-11-24       Impact factor: 7.853

4.  Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods.

Authors:  Rui-Juan Niu; Qing-Chuan Zheng; Ji-Long Zhang; Hong-Xing Zhang
Journal:  J Mol Model       Date:  2011-02-08       Impact factor: 1.810

5.  Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration.

Authors:  Kristine L P Garcia; Kathy Coen; Sharon Miksys; Anh Dzung Lê; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-02-05       Impact factor: 7.853

6.  Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse.

Authors:  Lei Li; Kunzhi Jia; Xin Zhou; Sarah E McCallum; Lindsay B Hough; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2013-09-17       Impact factor: 4.030

7.  Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.

Authors:  Sean C Gay; Manish B Shah; Jyothi C Talakad; Keiko Maekawa; Arthur G Roberts; P Ross Wilderman; Ling Sun; Jane Y Yang; Stephanie C Huelga; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2010-01-08       Impact factor: 4.436

8.  Structural and thermodynamic basis of (+)-α-pinene binding to human cytochrome P450 2B6.

Authors:  P Ross Wilderman; Manish B Shah; Hyun-Hee Jang; C David Stout; James R Halpert
Journal:  J Am Chem Soc       Date:  2013-07-03       Impact factor: 15.419

9.  Flavonoids from Pterogyne nitens as Zika virus NS2B-NS3 protease inhibitors.

Authors:  Caroline Sprengel Lima; Melina Mottin; Leticia Ribeiro de Assis; Nathalya Cristina de Moraes Roso Mesquita; Bruna Katiele de Paula Sousa; Lais Durco Coimbra; Karina Bispo-Dos- Santos; Kimberley M Zorn; Rafael V C Guido; Sean Ekins; Rafael Elias Marques; José Luiz Proença-Modena; Glaucius Oliva; Carolina Horta Andrade; Luis Octavio Regasini
Journal:  Bioorg Chem       Date:  2021-02-11       Impact factor: 5.275

10.  Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches.

Authors:  Pan-Fen Wang; Alicia Neiner; Thomas R Lane; Kimberley M Zorn; Sean Ekins; Evan D Kharasch
Journal:  Mol Pharm       Date:  2019-01-10       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.